Theravance Biopharma R&d Ip, LLC

Deciphera Pharmaceuticals, LLC

Gary E L Brandt

Paul Ross Fatheree

Cameron Smith

Lori Jean Van Orden

Steven D E Sullivan

Ryan Hudson

Jennifer Kozak

Glenn D Crater

Melanie A Kleinschek

Melissa Fleury

Robert Murray McKinnell

Anne-Marie Beausoleil

John R Jacobsen

Marta Dabros

Lan Jiang

Venkat R Thalladi

Jerry Nzerem

Dante D Podesto

Noah M Benjamin

Daniel L Flynn

Miroslav Rapta

Michael D Kaufman

Pierre-Jean Colson

Timothy Malcolm Caldwell

Gene Timothy Fass

Thiwanka Samarakoon

Hanumaiah Telikepalli

Disclosed is a compound of the formula: or a pharmaceutically-acceptable salt thereof. Also disclosed is a method of inhibiting a Janus kinase enzyme in a mammal using the compound.

3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor

The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.

Pyrimidine compound as JAK kinase inhibitor

The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

JAK inhibitors containing a 4-membered heterocyclic amide

The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

JAK kinase inhibitor compounds for treatment of respiratory disease

The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

Fused imidazo-piperidine JAK inhibitors

The invention provides compounds of formula (I):  which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

Growing community of inventors

Alameda, CA, United States of America

Gary E L Brandt